Autoantibodies in Breast Cancer Detection

Inclusion Criteria

• •All Cohorts:
• •Women age 18 and older
• •Understand and provide informed consent and HIPAA Authorization prior to initiation of any study-specific procedures
• •Cohort A:
• •Recent abnormal mammogram followed by a breast biopsy
• •Initial diagnosis of Stage I, II, III or IV invasive breast cancer
• •Cohort B:
• •Recent abnormal mammogram followed by a breast biopsy
• •Diagnosed benign breast tumor with high-risk pathology. This would include, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), flat epithelia atypia and phylloides
• •Cohort C:
• •Recent abnormal mammogram followed by a breast biopsy
• •Diagnosed benign breast tumor. This would include, but is not limited to, fibroadenoma, papilloma, fibrocystic changes, and Pseudoangiomatous stromal hyperplasia (PASH)
• •Cohort D:
• •Normal screening mammogram within the last 6 months